24123-89-5

Basic information

• Product Name: 2-benzylidene-1-azabicyclo[2.2.2]octan-3-one
• Synonyms: 1-azabicyclo[2.2.2]octan-3-one, 2-(phenylmethylene)-; 2-Benzylidenequinuclidin-3-one
• CAS NO: 24123-89-5
• Molecular Formula: C₁₄H₁₅NO
• Molecular Weight: 213.275
• Mol File: 24123-89-5.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 388.2°C at 760 mmHg
• Flash Point: 159.3°C
• Density: 1.17g/cm³
• Vapor Pressure: 3.12E-06mmHg at 25°C
• Refractive Index: 1.616
• CAS DataBase Reference: 2-benzylidene-1-azabicyclo[2.2.2]octan-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-benzylidene-1-azabicyclo[2.2.2]octan-3-one(24123-89-5)
• EPA Substance Registry System: 2-benzylidene-1-azabicyclo[2.2.2]octan-3-one(24123-89-5)

Safety Data

• Hazardous Substances Data: 24123-89-5(Hazardous Substances Data)

Usage

General Description

2-benzylidene-1-azabicyclo[2.2.2]octan-3-one is a chemical compound that belongs to the class of azabicyclic compounds. It is a synthetic organic compound that is commonly used in the field of medicinal chemistry and drug development. 2-benzylidene-1-azabicyclo[2.2.2]octan-3-one has been identified as a potential pharmacological agent, with studies showing its potential in various therapeutic applications. Its unique molecular structure makes it an interesting candidate for drug design and development, and it is being actively researched for its potential biological and pharmacological activities.

Upstream product

• 3731-38-2 3-Quinuclidinone 
• 100-52-7 benzaldehyde 
• 1193-65-3 3-quinuclidinone hydrochloride 

Downstream Products

• 78961-51-0 4-<(3'-Indolyl)benzyl>-3-hydroxyquinuclidine 
• 82955-24-6 3-phenyl-1,4,5-triazatricyclo[5.2.2.0^2,6]undec-5-ene 
• 82955-28-0 3,3'-Azinobis(2-benzylidenequinuclidine) 
• 78130-07-1 anti-(Z)-2-phenylmethylene-3-quinuclidone oxime 
• 78121-28-5 syn-(Z)-2-phenylmethylene-3-quinuclidone oxime 
• 78121-26-3 syn,trans-2-Benzylidene-3-oxoquinuclidine Oxime 
• 82955-30-4 2-Benzylidene-3-oxoquinuclidine phenylhydrazone 
• 167643-21-2 6-oxo-8-phenyl-3,4,5,6-tetrahydro-2H-1,4-ethano-1,5-naphthyridine 
• 162933-93-9 3-(3-oxoquinuclidin-2-yl)-1,2-diphenylpropanonitrile 
• 78961-46-3 syn-(E)-2-phenylmethylene-3-quinuclidone oxime hydrochloride 
• 1025962-76-8 2-(2-Bromo-2-nitro-1-phenyl-ethyl)-1-aza-bicyclo[2.2.2]octan-3-one 

Relevant articles and documents

Aminations and arylations by direct C-O activation for the design of 7,8-dihydro-6H-5,8-ethanopyrido[3,2-d]pyrimidines

The design of some novel disubstituted 7,8-dihydro-6H-5,8-ethanopyrido[3,2-d]pyrimidine derivatives is reported. The series was developed from quinuclidinone, which afforded versatile platforms bearing one lactam function in positionC-2 that were then used to create C-N or C-C bonds for SNAr or palladium-catalyzed cross-coupling reactions byin situC-O activation. The reaction conditions were optimized under microwave irradiation, and a wide range of amines or boronic acids were used to determine the scope and limitations of each method. To complete this study, the X-ray crystallographic data of 7,8-dihydro-6H-5,8-ethanopyrido[3,2-d]pyrimidine derivative49were used to formally establish the structures of the products.

QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, X, Y1, Y2, Y3 and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents

Malaria remains a significant infectious disease with even artemisinin-based therapies now facing resistance in the field. Development of new therapies is urgently needed, either by finding new compounds with unique modes of action, or by reversing resistance towards known drugs with 'chemosensitizers' or 'chemoreversal' agents (CRA). Concerning the latter, we have focused on the resistance mechanisms developed against chloroquine (CQ). We have synthesized a series of compounds related to previously identified CRAs, and found promising novel compounds. These compounds show encouraging results in a coumarin labeled chloroquine uptake assay, exhibiting a dose response in resensitising parasites to the antimalarial effects of chloroquine. Selected compounds show consistent potency across a panel of chloroquine and artemisinin sensitive and resistant parasites, and a wide therapeutic window. This data supports further study of CRAs in the treatment of malaria and, ultimately, their use in chloroquine-based combination therapies.